Abstract:
Cancer of the lungs is the second most frequent form of cancer overall and has the
greatest mortality rate because to its severe pathological abnormalities. In lung cancer,
abnormal cell proliferation causes the alveolar duct to clot. Lung cancer is difficult to
treat due to its clinical and biological heterogeneity, which necessitates the development
of new therapeutic approaches or the refinement of existing ones. To investigate this,
saikosaponin b2 was administered to mice with lung cancer caused by B(a)P. (SSb2).
BAP is considered a group one carcinogen by the International Agency for Research on
Cancer (IARC). Therefore, B(a)P may play a role in producing lung cancer. Albino
balb/c mice were given B(a)P on alternate days over a 4-week period to induce cancer,
with DMBA given weekly to encourage tumor growth. Beginning in the third week,
SSb2 was given daily for twenty days. The drug's potential anti-cancer effects were
studied by examining hepatic biomarkers, lung histology, and oxidative stress indicators.
Increases in SOD, CAT, GST, and GSH levels accompanied by decreases in MDA levels
and enhanced B(a)P detoxification after SSb2 treatment, which also improved liver
function. Histopathology data showed that as compared with the B(a)P alone group, SSb2
reduced inflammation, membrane blebbing, and alveolar structure began returning to
normal.
